MedPath

Changes in Biomarkers Associated With Use of Electronic Cigarettes

Not Applicable
Completed
Conditions
Biomarkers
Registration Number
NCT03084315
Lead Sponsor
University of Minnesota
Brief Summary

The objective of this clinical trial was to compare the effects of e-cigarettes with and without nicotine on patterns of combustible cigarette use and biomarkers of exposure to tobacco toxicants among African American smokers.

Detailed Description

This study compares patterns of e-cigarette use and the exposure to the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in African American smokers, randomized to ad lib e-cigarettes containing nicotine vs. no nicotine. We hypothesized that nicotine e-cigarettes would be used more than no-nicotine e-cigarettes, and that this would be associated with reduced use of combustible cigarettes. We hypothesized that nicotine e-cigarettes would result in more substitution for combusted cigarettes than no-nicotine e-cigarettes and result in lower levels of exposure to the tobacco-specific carcinogen NNAL. These results would be relevant for developing exposure reduction strategies for adult African American smokers.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
234
Inclusion Criteria
  1. self-identify as African American or Black;
  2. age 18 years or older;
  3. smoke at least five cigarettes daily for the past year;
  4. not interested in quitting smoking in the next 6 months;
  5. Willing to use e-cigarettes;
  6. Good physical health (no unstable medical or mental health condition);
  7. no contraindications for e-cigarette use.
Exclusion Criteria
  1. Recent unstable or untreated psychiatric diagnosis including substance abuse, as determined by the DSM-IV criteria;
  2. use in the past 30 days of tobacco or nicotine products including e-cigarettes, other than regular cigarettes;
  3. participation in a smoking cessation program in the past 30 days;
  4. pregnant or nursing.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in Biomarker Concentrations: Nicotine EquivalentsBaseline, Week 6

Change in concentration of nicotine equivalents in units of mmol/mg creatinine.

Change in Biomarker Concentrations: NNALBaseline, Week 6

Change in urinary concentration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in units of pmol/mg creatinine.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

DCRU

🇺🇸

Minneapolis, Minnesota, United States

DCRU
🇺🇸Minneapolis, Minnesota, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.